---
figid: PMC6629629__41419_2019_1769_Fig2_HTML
figtitle: 'Clinical update on head and neck cancer: molecular biology and ongoing
  challenges'
organisms:
- NA
pmcid: PMC6629629
filename: 41419_2019_1769_Fig2_HTML.jpg
figlink: /pmc/articles/PMC6629629/figure/Fig2/
number: F2
caption: EGFR, MET and NOTCH alterations promotes proliferation, migration and cellular
  survival via signalling through the RAS/RAF/ERK, PI3K and JAK/STAT pathways, all
  of which are regularly dysregulated in HNSCC. Disruption of the p53 pathway also
  leads to high levels of genomic instability. Green boxes show possible therapeutic
  agents either approved (*) or under investigation for clinical use in HNSCC. Information
  about the percentage of HNSCC cases showing either mutations or overexpression of
  the pathway as a whole shown in red boxes, where this data are available. Note,
  though activation of the JAK/Stat pathway is regularly seen in HNSCC, no mutations
  have yet been found–
papertitle: 'Clinical update on head and neck cancer: molecular biology and ongoing
  challenges.'
reftext: Elham Alsahafi, et al. Cell Death Dis. 2019 Aug;10(8):540.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.956635
figid_alias: PMC6629629__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC6629629__F2
ndex: e0088de4-dee7-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6629629__41419_2019_1769_Fig2_HTML.html
  '@type': Dataset
  description: EGFR, MET and NOTCH alterations promotes proliferation, migration and
    cellular survival via signalling through the RAS/RAF/ERK, PI3K and JAK/STAT pathways,
    all of which are regularly dysregulated in HNSCC. Disruption of the p53 pathway
    also leads to high levels of genomic instability. Green boxes show possible therapeutic
    agents either approved (*) or under investigation for clinical use in HNSCC. Information
    about the percentage of HNSCC cases showing either mutations or overexpression
    of the pathway as a whole shown in red boxes, where this data are available. Note,
    though activation of the JAK/Stat pathway is regularly seen in HNSCC, no mutations
    have yet been found–
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - .na.character
  - hop
  - bsk
  - Shc
  - drk
  - Sos
  - ras
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Stat92E
  - Raf
  - Akt
  - Pten
  - Dsor1
  - Mtor
  - Tor
  - rl
  - p53
  - betaTub60D
  - hth
  - Lamtor2
  - et
  - ten
  - AREG
  - EGF
  - TGFA
  - HBEGF
  - BTC
  - EREG
  - EPGN
  - EGFR
  - HGF
  - IL6
  - SOS1
  - NOTCH1
  - NOTCH2
  - NOTCH3
  - NOTCH4
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - GRB2
  - XYLT2
  - SOS2
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - PTEN
  - MAP2K1
  - MAP2K2
  - MTOR
  - MAPK3
  - MAPK1
  - MDM2
  - TP53
  - TP63
  - TP73
  - CDKN2A
  - S100A9
  - CDK2AP2
  - SUB1
  - RPP14
  - LAMTOR2
  - SF3B6
  - H3P8
  - Capmatinib
  - Afatinib
  - Erlotinib
  - Ruxolitinib
  - Trametinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
